News & Updates

Show Multimedia Only
Noninvasive UGN-102 therapy delivers durable response in recurrent LG-IR-NMIBC

Noninvasive UGN-102 therapy delivers durable response in recurrent LG-IR-NMIBC

05 Aug 2026 byStephen Padilla

Patients with recurrent low-grade intermediate-risk nonmuscle-invasive bladder cancer (LG-IR-NMIBC) who achieved an initial complete response (CR) to UGN-102 treatment tend to remain event-free 24 months later, according to phase III ENVISION trial.

Noninvasive UGN-102 therapy delivers durable response in recurrent LG-IR-NMIBC

05 Aug 2026
Resistance training lifts life quality in people with multiple sclerosis

Resistance training lifts life quality in people with multiple sclerosis

04 Aug 2026 byStephen Padilla

Individuals with multiple sclerosis may benefit from resistance training, which has been shown in a recent study to potentially improve quality of life (QoL), particularly in the domains related to physical and mental health.

Resistance training lifts life quality in people with multiple sclerosis

04 Aug 2026